Abstract
Rotavirus infection is the most common diarrheal disease worldwide in children under five years of age, and it often results in death. In recent years, research on the relationship between rotavirus and probiotics has shown that probiotics are effective against diarrhea. A clinical trial has reported that Bifidobacterium longum BORI reduced diarrhea induced by rotavirus. The present work investigated the anti-rotaviral effect of B. longum BORI by cytopathic effect observation and real time cell analyses. Our study found that B. longum BORI showed strong anti-rotaviral effect when incubated with MA104 cells prior to viral infection, suggesting that the probiotic does in fact interfere with the interaction of viruses and host cells. It is believed that the efficacy is due to low-molecular weight and non-protein components derived from B. longum BORI. This discovery can help broaden the industrial application of B. longum BORI, which has been proven to be a safe and effective probiotic.
Highlights
Rotavirus infection, the primary cause of death among children under five years of age, is caused by rotaviruses belonging to double-stranded RNA viruses, and presents symptoms including vomiting, fever, diarrhea, and dehydration [1]
We focused on B. longum BORI, which showed the reduction of diarrhea in the preceding study [10]
These results suggest that the anti-rotaviral efficacy of bacterial whole cell extract (BCE) is due to nonprotein substances
Summary
The primary cause of death among children under five years of age, is caused by rotaviruses belonging to double-stranded RNA viruses, and presents symptoms including vomiting, fever, diarrhea, and dehydration [1]. It is estimated that one-third of children under five years of age who are hospitalized for diarrhea have rotavirus infections, regardless of whether they live in advanced or developing countries [2,3] This condition is serious, as infants with severe dehydration due to diarrhea can die. In 2006 and 2008, two live oral rotavirus vaccines called RotaTeq and Rotarix, were approved by the US FDA for the prevention of rotavirus gastroenteritis in infants [5] These two vaccines are widely used globally as there is less risk of intussusception with the vaccines than with RotaShield and even WHO has recommended including these vaccines in national immunization schedules [5]. There is a need for alternative preventive measures that are economical and easy to use
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
